MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - January 24, 2011) -
MorphoSys AG /
MorphoSys Announces Clinical Milestone within Boehringer Ingelheim Alliance
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
CTA Filing in Late December 2010 Represented the Eighth Clinical Milestone
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today
has received a clinical milestone payment from Boehringer
connection with the regulatory filing of a clinical trial application
phase 1 trial of a HuCAL-derived antibody. The filing took place in
December 2010 making this the eighth clinical milestone met with partners
the year. Financial details are not disclosed.
"In 2010, we saw eight clinical milestones reached with five different
which surpassed our original expectations for the year of up to six
events," commented Dr. Marlies Sproll, Chief Scientific Officer of
"Today's news marks the start of the first clinical program
partnership with Boehringer Ingelheim."
MorphoSys's clinical pipeline now comprises ten partnered programs in
and five in Phase 2 development as well as the Company's proprietary
MOR103, which is in a Phase 1b/2a trial for rheumatoid arthritis, and
which is in a Phase 1 trial for chronic lymphocytic leukemia.
MorphoSys is an independent biotechnology company that develops novel
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical
MorphoSys has created a pipeline of more than 60 drug candidates. The
expanding its drug pipeline by adding new partnered programs, and by
portfolio of fully-owned therapeutic antibodies. For its proprietary
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-
is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis
patients. Via its business unit AbD Serotec, MorphoSys is expanding the
its technologies in the diagnostics and research markets. MorphoSys is
headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange
under the symbol "MOR". For further information,
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®
and RapMAT® are
registered trademarks of MorphoSys; arYla™ is a trademark of MorphoSys.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE